MX2019002996A - Nanopartículas como sustratos catalíticos para biodetección en tiempo real del desempeño humano y diagnóstico y métodos terapéuticos. - Google Patents

Nanopartículas como sustratos catalíticos para biodetección en tiempo real del desempeño humano y diagnóstico y métodos terapéuticos.

Info

Publication number
MX2019002996A
MX2019002996A MX2019002996A MX2019002996A MX2019002996A MX 2019002996 A MX2019002996 A MX 2019002996A MX 2019002996 A MX2019002996 A MX 2019002996A MX 2019002996 A MX2019002996 A MX 2019002996A MX 2019002996 A MX2019002996 A MX 2019002996A
Authority
MX
Mexico
Prior art keywords
nanoparticles
diagnostic
real
therapeutic methods
human performance
Prior art date
Application number
MX2019002996A
Other languages
English (en)
Inventor
Shad Thaxton C
U Palekar Rohun
M Mcmahon Kaylin
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of MX2019002996A publication Critical patent/MX2019002996A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4866—Evaluating metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02—Details of sensors specially adapted for in-vivo measurements
    • A61B2562/028—Microscale sensors, e.g. electromechanical sensors [MEMS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J35/00—Catalysts, in general, characterised by their form or physical properties
    • B01J35/30—
    • B01J35/393—
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Abstract

Aquí se proporcionan nanoestructuras que tienen un núcleo inorgánico y una capa lipídica capaz de unir un activador de lecitin colesterol acil transferasa (LCAT) tal como una apolipoproteína; también se proporcionan métodos para usar las nanopartículas y dispositivos y composiciones relacionados para evaluar el riesgo de desarrollar una enfermedad o afección, o para tratar la enfermedad o la afección.
MX2019002996A 2016-09-15 2017-09-15 Nanopartículas como sustratos catalíticos para biodetección en tiempo real del desempeño humano y diagnóstico y métodos terapéuticos. MX2019002996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395245P 2016-09-15 2016-09-15
PCT/US2017/051930 WO2018053368A1 (en) 2016-09-15 2017-09-15 Nanoparticles as catalytic substrates for real-time biosensing of human performance and diagnostic and therapeutic methods

Publications (1)

Publication Number Publication Date
MX2019002996A true MX2019002996A (es) 2019-09-18

Family

ID=61559804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002996A MX2019002996A (es) 2016-09-15 2017-09-15 Nanopartículas como sustratos catalíticos para biodetección en tiempo real del desempeño humano y diagnóstico y métodos terapéuticos.

Country Status (7)

Country Link
US (2) US20180074080A1 (es)
EP (1) EP3513200A4 (es)
JP (1) JP2019536003A (es)
AU (1) AU2017328956A1 (es)
CA (1) CA3036990A1 (es)
MX (1) MX2019002996A (es)
WO (1) WO2018053368A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011207563B2 (en) 2010-01-19 2016-03-10 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
WO2016085986A1 (en) 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
US10967072B2 (en) 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
WO2018237182A1 (en) * 2017-06-21 2018-12-27 Northwestern University LIPID NANOPARTICLES FOR MEASURING A CHRONIC AND ACUTE RESPONSE TO AN EXERCISE
WO2020231860A1 (en) * 2019-05-10 2020-11-19 Northwestern University Orally delivered lipid nanoparticles target and reveal gut cd36 as a master regulator of systemic lipid homeostasis with differential gender responses
WO2021055788A1 (en) * 2019-09-18 2021-03-25 Northwestern University High density lipoprotein-like nanoparticles as inducers of ferroptosis in cancer
WO2022099082A1 (en) * 2020-11-05 2022-05-12 President And Fellows Of Harvard College Fiber-optic integrated textiles with embedded freeze-dried cell-free reactions for wearable sensors
CN117460955A (zh) * 2021-06-04 2024-01-26 国立大学法人东京医科齿科大学 用于测量胆固醇外排能力的新方法
CN114134203B (zh) * 2021-11-26 2022-12-02 深圳市雷诺华科技实业有限公司 一种利用纳米酶进行高密度脂蛋白胆固醇测定的方法
CN114705742A (zh) * 2022-02-21 2022-07-05 南京理工大学 一种基于锌卟啉有机笼的仿生膜结构及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US216841A (en) * 1879-03-31 1879-06-24 Improvement in apparatus for disintegrating grain and distilling spirits
CN1874720B (zh) * 2003-09-03 2010-11-17 生命修复国际股份有限公司 个人诊断装置
US20080200838A1 (en) * 2005-11-28 2008-08-21 Daniel Goldberger Wearable, programmable automated blood testing system
US20090264720A1 (en) * 2008-04-17 2009-10-22 The Cooper Health System Wearable Automated Blood Sampling and Monitoring System
DK2288336T3 (en) * 2008-04-25 2017-03-13 Univ Northwestern NANOSTRUCTURES SUITABLE FOR COMPLEXATION OF CHOLESTEROL
AU2011207563B2 (en) * 2010-01-19 2016-03-10 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
AU2014212847A1 (en) * 2013-01-31 2015-09-17 Privail Inc. Testing device
WO2015023797A1 (en) * 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
US10078092B2 (en) * 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules

Also Published As

Publication number Publication date
US20200363437A1 (en) 2020-11-19
CA3036990A1 (en) 2018-03-22
US20180074080A1 (en) 2018-03-15
WO2018053368A1 (en) 2018-03-22
JP2019536003A (ja) 2019-12-12
AU2017328956A1 (en) 2019-04-04
EP3513200A1 (en) 2019-07-24
EP3513200A4 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
MX2019002996A (es) Nanopartículas como sustratos catalíticos para biodetección en tiempo real del desempeño humano y diagnóstico y métodos terapéuticos.
AU2018256633A1 (en) Therapy for enteric infections
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
WO2015173633A3 (en) Hdl therapy markers
MX2021011939A (es) Compuestos neuroactivos y metodos de uso de los mismos.
EA201892625A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1121529T1 (el) Σηματοδοτηση slit-robo για διαγνωση και θεραπεια νεφρικης νοσου
BR112013029271A2 (pt) cicatrização de tecido
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
ECSP12012309A (es) Anticuerpos hacia gdf8 humano
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112016008409A2 (pt) Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
NZ732241A (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
BRPI0920170A2 (pt) métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
WO2010054221A3 (en) Treatment of chronic inflammatory respiratory disorders